Roivant Sciences

Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old

Retrieved on: 
Wednesday, March 15, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Linda, 2020 Henry Ford Health System 200, Adolescence, Pediatrics, Quality of life, Common, Atopic dermatitis, Itch, Psoriasis, Stinger, Swelling, BSA, Irritation, Clinical research, Dermatitis, Body surface area, Nose, Patient, Roivant Sciences, Rady, Physician, Pain, FDA, Pharmacist, Diagnosis, Prescription, JD, Week, Rash, Folliculitis, Incidence, Headache, Plaque, Surveying, Pharmaceutical industry, Cosmetics, Dietary supplement, EASI, MD, Dermatology

“Atopic dermatitis, the most common type of eczema, affects more than 9.6 million children and 16.5 million adults in the United States.

Key Points: 
  • “Atopic dermatitis, the most common type of eczema, affects more than 9.6 million children and 16.5 million adults in the United States.
  • In the U.S., VTAMA cream is already approved for the topical treatment of plaque psoriasis in adults.
  • Importantly, VTAMA cream data indicated no safety or tolerability signals in this population including children as young as 2 years old.
  • “Atopic dermatitis can have a negative impact on the quality of life of diagnosed children as well as their families.

EQS-News: BIO-Europe Spring® 2023 is only a few weeks away

Retrieved on: 
Saturday, March 11, 2023
Sofinnova, VIVO, Evaluation, Novartis, Pfizer, Roivant Sciences, Nature Biotechnology, Partnering, Roche, Business development, Nathalie, Business, Fine chemical

EBD Group is thrilled to reunite on March 20–22, 2023 in Basel, Switzerland.

Key Points: 
  • EBD Group is thrilled to reunite on March 20–22, 2023 in Basel, Switzerland.
  • After being held digitally for the last three years, leading executives from around the world are eager to get back to face-to-face partnering.
  • We are currently looking to welcome more than 3,000 attendees, making this the largest BIO-Europe Spring® to date.
  • In addition, the event will cater to the needs of the entire value chain in the biotech and pharma sector.

Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement

Retrieved on: 
Tuesday, March 7, 2023
Royal, National academy, DNA, Alvan, Harvard Medical School, Science, Merck, Dana–Farber Cancer Institute, JANUVIA, Chromosome, Roivant Sciences, DNA repair, Institute of technology, Cell, Therapy, Technical University of Munich, Schering-Plough, Drug discovery, Human Proteome Organization, Proteomics, University, Research, Analytical and Bioanalytical Chemistry, Radiation therapy, UCB, FRSC, Cancer, Royal Society, SAB, Susan, AbbVie, United States Air Force Scientific Advisory Board, Patient, GSK, National Academy of Medicine, British Mass Spectrometry Society, The German, Pharmaceutical industry, Chemistry, Medicine

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company incubated by Roivant Sciences (Nasdaq: ROIV), today announced the formation of its Scientific Advisory Board (SAB).

Key Points: 
  • BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company incubated by Roivant Sciences (Nasdaq: ROIV), today announced the formation of its Scientific Advisory Board (SAB).
  • Covant uses its unprecedented high-throughput chemoproteomics platform to discover novel small molecule therapeutics against hard-to-drug immunology and oncology targets.
  • “This is a very exciting time for Covant as we continue to build our compelling pipeline of therapeutic programs,” said Dr. Ivan Cornella, Chief Scientific Officer of Covant.
  • “I am thrilled to welcome our new Scientific Advisory Board members.

Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update

Retrieved on: 
Thursday, March 2, 2023
Immune system, Safety, Arm, Roivant Sciences, RNA, VBR, PD-1, Clinical trial, Research, RNA interference, Initiate, HBsAg, Patient, HBV, Technology transfer, Assembly, PD-L1, Investment, COVID-19, Nivolumab, CFBV, Virology, Therapy, Cornerstone, Hepatitis B virus, Coronavirus, SARS-CoV-2, NA, Viral, IND, Pharmaceutical industry, Vaccine, Cryptocurrency

Preliminary data from the lead-in phase of the trial further validated AB-729’s capacity to reduce HBsAg.

Key Points: 
  • Preliminary data from the lead-in phase of the trial further validated AB-729’s capacity to reduce HBsAg.
  • We expect to announce preliminary data from patients receiving the combination of AB-729, NA therapy and IFN in the first half of 2023.
  • As of December 31, 2022, we had approximately 157.5 million common shares issued and outstanding, as well as approximately 15.5 million stock options outstanding.
  • Roivant Sciences Ltd. owned approximately 25% of our outstanding common shares as of December 31, 2022.

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

Retrieved on: 
Tuesday, February 28, 2023
TIL, Roivant Sciences, EPI, The Society, GSK, Survival, Research, Cell, Annual general meeting, GAAP, Gene, CAR, Immunotherapy, Patient, R, Neoplasm, ROR1, SITC, AP-1 transcription factor, Lyell, Cell proliferation, G&A, Society, Lung cancer, Cryptocurrency, Pharmaceutical industry, Vaccine, Medical imaging, IND, NR4A3

Initial clinical data from the Phase 1 trial of LYL797 are expected in the first half of 2024.

Key Points: 
  • Initial clinical data from the Phase 1 trial of LYL797 are expected in the first half of 2024.
  • LYL119 incorporates four of Lyell’s stackable reprogramming technologies, including two novel technologies – a genetic knockout of NR4A3 (NR4A3-KO) and Stim-R™.
  • The decrease in fourth quarter 2022 and increase in annual 2022 G&A expenses were both primarily driven by changes in non-cash stock-based compensation.
  • The increase in annual 2022 non-GAAP G&A expenses was driven by increased legal and corporate expenses and public company operating costs.

Roivant Sciences Announces Change to its Board of Directors

Retrieved on: 
Wednesday, February 22, 2023
FDA, Vant (band), Drug development, Psoriasis, Cryptocurrency, Management, Roivant Sciences

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its founder Vivek Ramaswamy has stepped down from the company’s board of directors to focus on his U.S. presidential campaign.

Key Points: 
  • BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its founder Vivek Ramaswamy has stepped down from the company’s board of directors to focus on his U.S. presidential campaign.
  • Vivek founded Roivant in 2014 with the vision of revolutionizing drug development.
  • Over the past decade, the FDA has granted six FDA approvals for medicines developed at Vants launched by Roivant, including VTAMA, approved for plaque psoriasis in 2022.
  • We are grateful for Vivek’s contributions to the board and to the organization, and we wish him well in his future endeavors,” said Matt Gline, CEO of Roivant.

Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results

Retrieved on: 
Tuesday, February 14, 2023
Oxford Biomedica, SIOX, Nine Months, Workforce, UMMS, Research, University of Massachusetts, RSL, Roivant Sciences, Cryptocurrency, Pharmaceutical industry

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal third quarter ended December 31, 2022.

Key Points: 
  • –  Operating Cash Outflows for the Nine Months Ended December 31, 2022 decreased by $23.8 million or 56% versus the prior year period
    –  $46.1 million of cash and cash equivalents as of December 31, 2022, a strong cash position as the Company prepares for liquidation and dissolution, subject to stockholder approval
    NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal third quarter ended December 31, 2022.
  • Research and development expenses were $1.9 million for the three months ended December 31, 2022 and $21.3 million for the three months ended December 31, 2021.
  • General and administrative expenses were $2.6 million for the three months ended December 31, 2022 and $4.1 million for the three months ended December 31, 2021.
  • The net loss for the fiscal third quarter ended December 31, 2022 was $4.0 million, or $0.05 per share, compared to a net loss of $25.5 million, or $0.35 per share, in the fiscal third quarter ended December 31, 2021.

MYOVANT SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV

Retrieved on: 
Wednesday, January 25, 2023
Biotechnology, Health, Professional Services, Pharmaceutical, Legal, Sale, Roivant Sciences, NYSE, KSF

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Myovant Sciences (NYSE: MYOV) to Sumitomo Pharma Co., Ltd.

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Myovant Sciences (NYSE: MYOV) to Sumitomo Pharma Co., Ltd.
  • Under the terms of the proposed transaction, shareholders of Myovant will receive only $27.00 in cash for each share of Myovant that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer

Retrieved on: 
Friday, February 3, 2023
Gene editing, Immunotherapy, Royal College of Physicians and Surgeons of Canada, Therapy, Surgeon, University, Royal college, Bachelor, Drug development, Queen, Acquisition, Patient, Drug, Biochemistry, Cross Cancer Institute, Translation, Internal medicine, Research, Oncology, Cell, Amgen, Queen's University, Physician, Treadwell, Oklahoma Office of the Chief Medical Examiner, Roivant Sciences, Pharmaceutical industry, Eterna

NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer.

Key Points: 
  • NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer.
  • Dr. Sidhu was most recently the Chief Medical Officer at Brooklyn (now Eterna) ImmunoTherapeutics, a gene editing and cell therapy company where he advanced multiple novel programs.
  • Previously, Dr. Sidhu served as Executive Vice President and Chief Medical officer at Roivant Sciences.
  • Roger was also the Chief Medical Officer at Cell Design Labs, up until its acquisition by the Gilead subsidiary Kite, where he subsequently served as VP, Clinical Development.

Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer

Retrieved on: 
Friday, February 3, 2023
Gene editing, Immunotherapy, Royal College of Physicians and Surgeons of Canada, Therapy, Surgeon, University, Royal college, Bachelor, Drug development, Queen, Acquisition, Patient, Drug, Biochemistry, Cross Cancer Institute, Translation, Internal medicine, Research, Oncology, Cell, Amgen, Queen's University, Physician, Treadwell, Oklahoma Office of the Chief Medical Examiner, Roivant Sciences, Pharmaceutical industry, Eterna

NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer.

Key Points: 
  • NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Treadwell Therapeutics, a clinical-stage, global biotechnology company developing novel, first in class therapeutics for highly aggressive cancers, today announced that it has appointed Roger Sidhu, M.D., as Chief Medical Officer.
  • Dr. Sidhu was most recently the Chief Medical Officer at Brooklyn (now Eterna) ImmunoTherapeutics, a gene editing and cell therapy company where he advanced multiple novel programs.
  • Previously, Dr. Sidhu served as Executive Vice President and Chief Medical officer at Roivant Sciences.
  • Roger was also the Chief Medical Officer at Cell Design Labs, up until its acquisition by the Gilead subsidiary Kite, where he subsequently served as VP, Clinical Development.